Drugs like Zepbound and Wegovy are intended for people who are overweight. Some patients are using them after bariatric surgery to keep pounds from creeping back. Others may just want to lose a few pounds.
One researcher found patients on the weight loss drugs may not be getting enough essential vitamins and nutrients.
As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now.
AI:Researchers and doctors are investigating why GLP-1 drugs fail to work for approximately 50% of users, leading to a shift toward more personalized obesity care that addresses individual biological drivers, similar to modern cancer treatment models.Open